Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 9/20 | 0.38 |
| ▸ | BPTF | Q12830 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | QPCT | Q16769 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | MTOR | P42345 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8251051 | 0.87 | IDH1 (0.38) | IDH1HDAC1HDAC8HDAC6QPCT | |
| SCHEMBL8256262 | 0.84 | PIK3CA (0.37) | IDH1HDAC1HDAC8HDAC6QPCT | |
| SCHEMBL8125549 | 0.82 | HDAC1 (0.35) | IDH1BPTFHDAC1HDAC8HDAC6 | |
| SCHEMBL15152621 | 0.81 | IDH1 (0.35) | IDH1HDAC1HDAC8HDAC6QPCT | |
| SCHEMBL18770297 | 0.81 | IDH1 (0.33) | IDH1HDAC1HDAC8HDAC6QPCT | |
| SCHEMBL6675442 | 0.78 | MAOB (0.47) | QPCT | |
| SCHEMBL6098143 | 0.78 | CMA1 (0.36) | IDH1BPTFQPCT | |
| SCHEMBL6607557 | 0.77 | IDH1 (0.37) | IDH1BPTFHDAC1HDAC8HDAC6 | |
| SCHEMBL6625580 | 0.77 | IDH1 (0.37) | IDH1BPTFHDAC1HDAC8HDAC6 | |
| SCHEMBL17287889 | 0.76 | HSP90AA1 (0.42) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150336992-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG FÜR KOMBINATORISCHE CHEMIE (DE) | 2015-11-26 | — | — | US | disclosed |
| US-9133213-B2 | Oxazolidinone-quinolone hybrid antibiotics | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2015-09-15 | — | — | US | disclosed |
| EP-1709044-B2 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2013-11-20 | — | — | EP | disclosed |
| US-20130296275-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2013-11-07 | — | — | US | disclosed |
| US-8501774-B2 | Oxazolidinone-quinolone hybrid antibiotics | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20120142635-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-06-07 | — | — | US | disclosed |
| US-8158797-B2 | Oxazolidinone-quinolone hybrid antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-04-17 | — | — | US | disclosed |
| EP-1709044-B1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080027040-A1 | Oxazolidinone-Quinolone Hybrid Antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE (DE) | 2008-01-31 | — | — | US | disclosed |
| EP-1709044-A2 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005058888-A2 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336992-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | OXA1L, TOP1, TOP2A | IDH1 607/4885BPTF 906/4885HDAC1 893/4885 |
| US-20120142635-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | OXA1L, TOP1, TOP2A | IDH1 607/4885BPTF 906/4885HDAC1 893/4885 |
| US-20080027040-A1 | Oxazolidinone-Quinolone Hybrid Antibiotics | OXA1L, TOP1, TOP2A | IDH1 607/4885BPTF 906/4885HDAC1 893/4885 |
| US-20130296275-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | OXA1L, TOP1, TOP2A | IDH1 607/4885BPTF 906/4885HDAC1 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.